Viridian Therapeutics (VRDN) director receives 32,341 options at $18.48

Rhea-AI Filing Summary

Viridian Therapeutics director Arlene Morris received a grant of 32,341 stock options. These options give her the right to buy an equal number of Viridian common shares at an exercise price of $18.48 per share and expire on July 1, 2036.

The option vests in full on the earlier of July 1, 2027 or Viridian’s 2027 annual meeting of stockholders, as long as she continues serving on the company’s Board of Directors. After this grant, she holds 32,341 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Morris Arlene

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	32,341	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 32,341 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 32,341 options Exercise price: $18.48 per share Expiration date: July 1, 2036 +3 more

6 metrics

Stock options granted 32,341 options Grant to director Arlene Morris on July 1, 2026

Exercise price $18.48 per share Strike price for Viridian common stock under the option

Expiration date July 1, 2036 Option term end date

Underlying shares 32,341 shares Viridian common stock underlying the option grant

Post-grant derivative holdings 32,341 derivative securities Total options held directly after this transaction

Vesting trigger date July 1, 2027 Earlier of this date or 2027 annual meeting, subject to board service

Key Terms

Stock Option (Right to Buy), exercise price, annual meeting of stockholders, Board of Directors, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "18.4800""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

annual meeting of stockholders financial

"the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service"

Board of Directors financial

"continued service on the Board of Directors of the Issuer"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 04:15 PM Accepted by SEC EDGAR 07/02/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Morris Arlene

(Last) (First) (Middle)

C/O VIRIDIAN THERAPEUTICS, INC.

221 CRESCENT STREET, SUITE 103A

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Viridian Therapeutics, Inc.\DE [ VRDN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$18.48	07/01/2026		A		32,341		(1)	07/01/2036	Common Stock	32,341	$0.00	32,341	D

Explanation of Responses:

1. The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.

	/s/ Jennifer Tousignant, Attorney-in-fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Viridian Therapeutics (VRDN) director Arlene Morris report in this Form 4?

Arlene Morris reported receiving a grant of stock options in Viridian Therapeutics. The award covers 32,341 options to buy common stock and reflects compensation for her role on the Board of Directors, rather than an open-market purchase or sale of shares.

How many Viridian Therapeutics (VRDN) stock options were granted to Arlene Morris and at what price?

Arlene Morris was granted 32,341 stock options in Viridian Therapeutics. Each option allows her to purchase one share of common stock at an exercise price of $18.48 per share, providing potential future ownership if she chooses to exercise the options.

When do Arlene Morris’s Viridian Therapeutics (VRDN) stock options vest?

The options vest in full on the earlier of July 1, 2027 or Viridian’s 2027 annual meeting of stockholders. Vesting is conditioned on her continued service on the company’s Board of Directors through that date, aligning the award with ongoing board tenure.

When do the Viridian Therapeutics (VRDN) stock options granted to Arlene Morris expire?

The stock options granted to Arlene Morris expire on July 1, 2036. After that date, any unexercised options become worthless, so the grant provides a long-term window during which she may choose to exercise and purchase Viridian common shares.

Is Arlene Morris’s Viridian Therapeutics (VRDN) option grant an open-market stock transaction?

No, the filing shows a grant of stock options as compensation, not an open-market trade. The transaction code is “A” for a grant or award, meaning she received options directly from Viridian rather than buying or selling existing shares on the market.